On Monday, biotechnology company Moderna announced they will be seeking approval for emergency use authorization from the Food and Drug Administration for their COVID-19 vaccine candidate.
Moderna joins Pfizer as the two leading groups to present a vaccine for possible emergency use authorization in a wide race by many companies to present a much-needed vaccination for the novel coronavirus.
Just as Dec. 11 has been said as the target date to view Pfizer’s proposal, Dec. 17 has been slated as the earliest date the FDA could review the vaccine.
Moderna has stated that the vaccine is 94.1 percent effective at preventing coronavirus cases and has not seen any new possible safety concerns since commencing phase three trials earlier in the month.
